Dr. Quinn is the Chief Executive Officer at Aeglea and most recently served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma until the company’s acquisition by Alexion Pharmaceuticals. During his tenure at Synageva, he played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the company’s research and development organization and rare disease drug pipeline. Prior to Synageva, Dr. Quinn served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. He received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London. Dr. Quinn currently serves on the board of Kaleido and Generation Bio.